Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers  (PDF 9.47 MB)

  Published:

  28 October 2021

• Final appraisal determination committee papers  (PDF 1.25 MB)

  Published:

  28 October 2021